Home Daily Intelligence Tracker
    • Plans Blog Contact
    Assertio Therapeutics Inc logo
    ASRT

    Assertio Therapeutics Inc

    MaveScore 35 Low model confidence
    Last Price US$23.50 As of Jun 29, 2026
    Market Cap US$151.6m Company size context
    7D Performance 0.00% Past 7 days
    1Y Performance N/A Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jun 29, 2026

    13 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 35 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Partial or delayed snapshot

    Quality

    10/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    7/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    5/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    13/15 Strong

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Assertio Therapeutics Inc Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including a Read More

    Assertio Therapeutics Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Assertio Therapeutics Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Mar 16, 2026

    Quarterly result summary

    Revenue was $0.4M (reported); EPS was -$1 (reported).

    Revenue $0.4M reported
    EPS -$1 reported
    Net loss -$0M reported
    Adjusted EBITDA $22.7M reported

    What changed

    • Revenue reported to $0.4M; EPS reported to -$1.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 08, 2026 SEC filing 10-K Mar 16, 2026 SEC filing 8-K Mar 16, 2026 SEC filing 10-Q Nov 10, 2025 SEC filing 8-K Nov 10, 2025 Earnings release Earnings release Nov 10, 2025 SEC filing 10-Q Aug 11, 2025 SEC filing 8-K Aug 11, 2025 Earnings release Earnings release Aug 11, 2025 SEC filing 10-Q May 12, 2025

    Recent News



    Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2023 Earnings Call Transcript
    1 hour ago
    Assertio Holdings Projects Positive Growth in 2024 with Anticipated Sales and EBITDA
    13 hours ago
    Assertio Holdings Inc (ASRT) Becoming More Attractive for Investors – Knox Daily
    14 hours ago

    Earnings Per Share

    Score 3.00/5
    Assertio Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 1.66/5
    Assertio Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Assertio The... ASRT US$151.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.01/5
    Assertio Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Assertio The... ASRT US$151.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 1.53/5
    Assertio Therapeutics Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Assertio The... ASRT US$151.6m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Assertio Therapeutics Inc logo

    Assertio Therapeutics Inc

    US$23.50

    US$151.6m

    0.00%

    N/A